DK1187603T3 - Kombinationsterapi tl at bevirke vægttab og at behandle obesitet - Google Patents

Kombinationsterapi tl at bevirke vægttab og at behandle obesitet

Info

Publication number
DK1187603T3
DK1187603T3 DK00939884T DK00939884T DK1187603T3 DK 1187603 T3 DK1187603 T3 DK 1187603T3 DK 00939884 T DK00939884 T DK 00939884T DK 00939884 T DK00939884 T DK 00939884T DK 1187603 T3 DK1187603 T3 DK 1187603T3
Authority
DK
Denmark
Prior art keywords
weight loss
combination therapy
treat obesity
cause weight
phentermine
Prior art date
Application number
DK00939884T
Other languages
Danish (da)
English (en)
Inventor
Thomas Najarian
Original Assignee
Vivus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivus Inc filed Critical Vivus Inc
Application granted granted Critical
Publication of DK1187603T3 publication Critical patent/DK1187603T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DK00939884T 1999-06-14 2000-06-14 Kombinationsterapi tl at bevirke vægttab og at behandle obesitet DK1187603T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13902299P 1999-06-14 1999-06-14
US17856300P 2000-01-26 2000-01-26
US18126500P 2000-02-09 2000-02-09
PCT/US2000/016434 WO2000076493A1 (en) 1999-06-14 2000-06-14 Combination therapy for effecting weight loss and treating obesity

Publications (1)

Publication Number Publication Date
DK1187603T3 true DK1187603T3 (da) 2007-12-17

Family

ID=27385274

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00939884T DK1187603T3 (da) 1999-06-14 2000-06-14 Kombinationsterapi tl at bevirke vægttab og at behandle obesitet

Country Status (10)

Country Link
EP (5) EP2305227B1 (el)
AT (1) ATE369126T1 (el)
AU (1) AU770068B2 (el)
CA (2) CA2377330C (el)
CY (1) CY1106974T1 (el)
DE (1) DE60035870T2 (el)
DK (1) DK1187603T3 (el)
ES (4) ES2542868T3 (el)
PT (1) PT1187603E (el)
WO (1) WO2000076493A1 (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7553818B2 (en) 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
ES2260261T3 (es) 2000-07-07 2006-11-01 Ortho-Mcneil Pharmaceutical, Inc. Derivados anticonvulsivos utiles para la prevencion del desarrollo de diabetes mellitus tipo ii y del sindrome x.
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
JP2004518718A (ja) * 2000-10-30 2004-06-24 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗糖尿病薬および抗痙攣薬を含んで成る併用療法
AU2002227052A1 (en) * 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
CA2478183C (en) 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
EP1505967B1 (en) 2002-05-17 2016-07-13 Duke University Method for treating obesity
JP2006511543A (ja) * 2002-12-13 2006-04-06 シラグ・アクチエンゲゼルシヤフト 安定なトピラメート製剤
DK1617832T3 (da) 2003-04-29 2008-07-07 Orexigen Therapeutics Inc Præparater til påvirkning af vægttab
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005070461A2 (en) * 2004-01-13 2005-08-04 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
BRPI0610864A2 (pt) 2005-05-20 2010-08-03 Janssen Pharmaceutica Nv processo para preparação de derivados de sulfamida
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
TW200812573A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US7780730B2 (en) 2006-09-25 2010-08-24 Iyad Saidi Nasal implant introduced through a non-surgical injection technique
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
KR20190042766A (ko) * 2006-11-09 2019-04-24 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
AU2014213552B2 (en) * 2007-06-13 2016-11-24 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
US8071557B2 (en) 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
EP2340246A2 (en) 2008-06-23 2011-07-06 Janssen Pharmaceutica, N.V. Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2010059586A1 (en) 2008-11-19 2010-05-27 Entrigue Surgical, Inc. Apparatus and methods for correcting nasal valve collapse
BR112012016783A2 (pt) 2010-01-11 2015-09-01 Orexigen Therapeutics Inc "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
WO2013028909A1 (en) * 2011-08-25 2013-02-28 Sova Pharmaceuticals, Inc. Combination therapy for the treatment of sleep-related breathing disorders
KR20200035501A (ko) 2012-06-06 2020-04-03 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
US9480594B2 (en) 2013-02-27 2016-11-01 Spirox, Inc. Nasal implants and systems and methods of use
WO2014134477A1 (en) * 2013-02-28 2014-09-04 Livelight Llc Methods and systems for treating overweight individuals
BR112016011747B1 (pt) 2013-12-05 2020-11-24 Givaudan Sa Uso de um composto modificador de sabor, composiçao comestivel contendo o referido composto bem como metodo para conferir, intensificar ou modificar um sabor umami e/ou salgado em um produto comestivel
CA2958213A1 (en) 2014-08-26 2016-03-03 Spirox, Inc. Nasal implants and systems and method of use
KR20180059863A (ko) 2015-09-25 2018-06-05 스파이록스 인코포레이티드 코 임플란트들 및 시스템들 및 사용 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
FR2684101B1 (fr) * 1991-11-22 1993-12-31 Adir Cie Nouveaux derives de benzoate d'ethanolamine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
US5498629A (en) 1993-12-23 1996-03-12 Ortho Pharmaceutical Corporation Anticonvulsant pseudofructopyranose sulfamates
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
US5795895A (en) 1997-06-13 1998-08-18 Anchors; J. Michael Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування

Also Published As

Publication number Publication date
ATE369126T1 (de) 2007-08-15
EP1187603A1 (en) 2002-03-20
DE60035870T2 (de) 2008-05-08
EP1187603B1 (en) 2007-08-08
CA2377330A1 (en) 2000-12-21
WO2000076493A1 (en) 2000-12-21
EP2305227A1 (en) 2011-04-06
EP2305226B1 (en) 2015-05-06
EP2305227B1 (en) 2015-05-06
PT1187603E (pt) 2007-11-16
AU770068B2 (en) 2004-02-12
EP1187603A4 (en) 2004-02-11
EP2305226A1 (en) 2011-04-06
EP2305228B1 (en) 2015-05-06
CA2686633A1 (en) 2000-12-21
ES2291215T3 (es) 2008-03-01
CY1106974T1 (el) 2012-09-26
EP2308481B1 (en) 2015-05-06
ES2542891T3 (es) 2015-08-12
EP2308481A1 (en) 2011-04-13
ES2542868T3 (es) 2015-08-12
EP2305228A1 (en) 2011-04-06
CA2377330C (en) 2009-11-24
AU5489600A (en) 2001-01-02
DE60035870D1 (de) 2007-09-20
ES2542892T3 (es) 2015-08-12

Similar Documents

Publication Publication Date Title
DK1187603T3 (da) Kombinationsterapi tl at bevirke vægttab og at behandle obesitet
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
CY1107314T1 (el) Μεθοδος θεpαπευτικης αγωγης ασθενων προσβεβλημενων με σκληρυνση κατα πλακας χρησιμοποιωντας συναινετικη ιντepφepονη
DK1333887T3 (da) Kombinationsbehandling omfattende antidiabetiske og antikonvulsive midler
DK0841949T3 (da) Anvendelse af saccharid-konjugater
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
DK0754176T3 (da) Hidtil ukendte carbamater og urinstoffer som modifikatorer for multidrugsresistens
TR200102499T2 (tr) Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
CY1113610T1 (el) Συνθεσεις και μεθοδοι για αγωγη μιτοχονδριακων παθησεων
TR199801315T2 (xx) X sendromunun tedavisi i�in bir ppar-alpha ve ppar-gamma antagonistinin kullan�lmas�.
BR9814923A (pt) Método para tratamento de doença de alzheimer
ATE232396T1 (de) Oxydiertes thymosin beta 4
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
NO984160L (no) FremgangsmÕte for behandling eller forebyggelse av interstitiell cystitt
ATE306977T1 (de) Schaukel für behinderte
TR199801289T2 (en) Terap�tik bile�ikler.
NO20053023L (no) Synergistisk kombinasjon omfattende roflumilas og (R,R)-formoterol
ATE139698T1 (de) Mittel zur behandlung chronischer ermüdungserscheinungen
EP1825851A3 (en) Combination therapy for effecting weight loss and treating obesity
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
BR0012318A (pt) Compostos semelhantes a amino ceramida e métodos terapêuticos de uso
CY1109771T1 (el) Η χρηση της φορμοτερολης στην προφυλακτικη και/ή θεραπευτικη αντιμετωπιση της μυικης απωλειας και/ή του καχεκτικου συνδρομου τα οποια συνδεονται με τις καταβολικες συνθηκες ορισμενων παθησεων. οπως ο καρκινος, to aids, οι μολυνσεις, ο διαβητης και αλλες
TW200501958A (en) A therapeutic agent for treating a behavioral disorder